| Summary: | Aggregation of amyloid-β (aβ) peptides into toxic oligomers, fibrils, and plaques is central in the molecular pathogenesis of Alzheimer’s disease (AD) and is the primary focus of AD diagnostics. Disaggregation or elimination of toxic aβ aggregates in patients is important for delaying the progression of neurodegenerative disorders in AD. Recently, 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS) was introduced as a chemical agent that binds with toxic aβ aggregates and transforms them into monomers to reduce the negative effects of aβ aggregates in the brain. However, the mechanism of aβ disaggregation by EPPS has not yet been completely clarified. In this study, an electrochemical impedimetric immunosensor for aβ diagnostics was developed by immobilizing a specific anti-amyloid-β (aβ) antibody onto a self-assembled monolayer functionalized with a new interdigitated chain-shaped electrode (anti-aβ/SAM/ICE). To investigate the ability of EPPS in recognizing AD by extricating aβ aggregation, commercially available aβ aggregates (aβ<sub>agg</sub>) were used. Electrochemical impedance spectroscopy was used to probe the changes in charge transfer resistance (R<sub>ct</sub>) of the immunosensor after the specific binding of biosensor with aβ<sub>agg</sub>. The subsequent incubation of the aβ<sub>agg</sub> complex with a specific concentration of EPPS at different time intervals divulged AD progression. The decline in the R<sub>ct</sub> of the immunosensor started at 10 min of EPPS incubation and continued to decrease gradually from 20 min, indicating that the accumulation of aβ<sub>agg</sub> on the surface of the anti-aβ/SAM/ICE sensor has been extricated. Here, the kinetic disaggregation rate <i>k</i> value of aβ<sub>agg</sub> was found to be 0.038. This innovative study using electrochemical measurement to investigate the mechanism of aβ<sub>agg</sub> disaggregation by EPPS could provide a new perspective in monitoring the disaggregation periods of aβ<sub>agg</sub> from oligomeric to monomeric form, and then support for the prediction and handling AD symptoms at different stages after treatment by a drug, EPPS.
|
|---|
